This review aims to understand the current evidence on the clinical significance of MUC5AC expression in PDA-tumor tissues and evaluate its use as a potential molecular biomarker (specifically as predictive, prognostic, monitoring, and response). The gene discussed is MUC5AC; the disease is Patent ductus arteriosus.